Skip to content
CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to Give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • ASCO 2016 Update: Immunotherapy & Melanoma: The Path to Progress

    Improved approaches for treating patients with melanoma.

    June 16, 2016| Arthur N. Brodsky, PhD
  • FDA Approval Expands Immunotherapy Options for Advanced Melanoma

    Immunotherapy combinations continue to shine against melanoma.

    January 27, 2016| Arthur N. Brodsky, PhD
  • FDA Approves Immunotherapy to Help Prevent Relapse of Melanoma

    The immunotherapy drug ipilimumab (Yervoy®) can now be used to help prevent relapse after surgery.

    October 30, 2015| Matthew Tontonoz
  • FDA Approves First in a New Class of Immunotherapies

    Amgen’s oncolytic virus immunotherapy, T-VEC, gets the green light from the FDA.

    October 27, 2015| Matthew Tontonoz
  • In a First, FDA Approves Immunotherapy Combination for Advanced Melanoma

    The approval of a combination of two immunotherapy drugs for melanoma represents a treatment milestone.

    October 1, 2015| Matthew Tontonoz
  • Jimmy Carter to Receive Immunotherapy for Melanoma

    The former president will receive a drug called pembrolizumab, a PD-1-blocking antibody.

    August 21, 2015| Matthew Tontonoz
  • European Regulators Approve Pembrolizumab (Keytruda) as First-line Treatment of Advanced Melanoma

    The decision makes pembrolizumab the second PD-1-blocking drug to receive approval in Europe.

    July 22, 2015| Matthew Tontonoz
  • Merck’s PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced Melanoma

    Data from a phase III trial indicate that Keytruda stands ready to become standard-of-care for advanced melanoma.

    March 24, 2015| Matthew Tontonoz
  • New Cancer Immunotherapy Opdivo Approved by FDA

    Just hours ago, the FDA approved Bristol-Myers Squibb's PD-1 drug for melanoma.

    December 22, 2014| Jill O'Donnell-Tormey, PhD
Previous Page
1 2 3 4 5
Next Page

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to Give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute